241 related articles for article (PubMed ID: 35247393)
1. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
McCarthy BE; McClelland RL; Appleby DH; Moutchia JS; Minhas JK; Min J; Mazurek JA; Smith KA; Fritz JS; Pugliese SC; Urbanowicz RJ; Holmes JH; Palevsky HI; Kawut SM; Al-Naamani N
Chest; 2022 Aug; 162(2):436-447. PubMed ID: 35247393
[TBL] [Abstract][Full Text] [Related]
2. Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
Ventetuolo CE; Moutchia J; Baird GL; Appleby DH; McClelland RL; Minhas J; Min J; Holmes JH; Urbanowicz RJ; Al-Naamani N; Kawut SM
Ann Am Thorac Soc; 2023 Jan; 20(1):58-66. PubMed ID: 36053665
[No Abstract] [Full Text] [Related]
3. Electrocardiographic Abnormalities and Their Association with Outcomes in Randomized Clinical Trials of Pulmonary Arterial Hypertension.
Minhas J; Moutchia J; Al-Naamani N; Mazurek JA; Holmes JH; Appleby D; Smith KA; Fritz JS; Pugliese SC; Palevsky HI; Kawut SM
Ann Am Thorac Soc; 2024 Jun; 21(6):858-865. PubMed ID: 38241602
[No Abstract] [Full Text] [Related]
4. Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
Pan HM; McClelland RL; Moutchia J; Appleby DH; Fritz JS; Holmes JH; Minhas J; Palevsky HI; Urbanowicz RJ; Kawut SM; Al-Naamani N
Eur Respir J; 2023 Jul; 62(1):. PubMed ID: 37169384
[TBL] [Abstract][Full Text] [Related]
5. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
[No Abstract] [Full Text] [Related]
6. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.
Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Holmes JH; Minhas J; Mazurek JA; Palevsky HI; Ventetuolo CE; Kawut SM
Eur Heart J; 2024 Jun; 45(21):1937-1952. PubMed ID: 38416633
[TBL] [Abstract][Full Text] [Related]
8. Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.
Degano B; Sitbon O; Savale L; Garcia G; O'Callaghan DS; Jaïs X; Humbert M; Simonneau G
Chest; 2010 Jun; 137(6):1297-303. PubMed ID: 20118205
[TBL] [Abstract][Full Text] [Related]
9. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Kuang HY; Li Q; Du HA; Chen M; Yin YH
Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
[TBL] [Abstract][Full Text] [Related]
11. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
12. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.
Poms AD; Turner M; Farber HW; Meltzer LA; McGoon MD
Chest; 2013 Jul; 144(1):169-176. PubMed ID: 23348820
[TBL] [Abstract][Full Text] [Related]
13. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
Porhownik NR; Myers R; Bshouty Z
Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
[TBL] [Abstract][Full Text] [Related]
14. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
15. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
[TBL] [Abstract][Full Text] [Related]
16. A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States.
Divers C; Platt D; Wang E; Lin J; Lingohr-Smith M; Mathai SC
J Manag Care Spec Pharm; 2017 Jan; 23(1):92-104. PubMed ID: 28025931
[TBL] [Abstract][Full Text] [Related]
17. Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension.
Heresi GA; Rao Y
Lung; 2020 Dec; 198(6):933-938. PubMed ID: 33211166
[TBL] [Abstract][Full Text] [Related]
18. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
He CJ; Chen SJ; Wang J; Zhu CY; Yin YH
Pulm Pharmacol Ther; 2015 Jun; 32():24-8. PubMed ID: 25843006
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.
Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M
Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
